CA-9 Levels and Breast Cancer Treatment Outcomes
Author Information
Author(s): Span P N, Bussink J, Manders P, Beex L V A M, Sweep C G J
Primary Institution: University Medical Centre Nijmegen
Hypothesis
The study aims to assess CA9 expression levels in breast cancer samples and correlate them with treatment outcomes.
Conclusion
CA9 expression is associated with poor treatment outcomes in breast cancer patients, particularly in high-grade, steroid receptor-negative tumors.
Supporting Evidence
- CA9 expression levels were higher in high-grade tumors compared to lower grades.
- CA9 levels were significantly associated with steroid hormone receptor status.
- Younger age and higher number of involved lymph nodes were linked to poorer relapse-free survival.
Takeaway
This study found that a protein called CA9 can help doctors understand which breast cancer patients might not respond well to certain treatments.
Methodology
The study used real-time quantitative RT-PCR to measure CA9 expression in breast cancer tissue samples and correlated these levels with relapse-free survival.
Potential Biases
Potential selection bias due to the retrospective nature of the study and treatment decisions made prior to the study.
Limitations
The study is retrospective and may be influenced by selection bias due to treatment decisions based on consensus recommendations.
Participant Demographics
Median age of participants was 60 years, with a range from 31 to 88 years; all had unilateral, operable breast cancer.
Statistical Information
P-Value
p<0.001 for steroid receptor status
Confidence Interval
95% CI for CA9 interaction with chemotherapy: 1.07–1.61; for endocrine therapy: 1.20–1.66
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website